President & CEO of SciClone Pharmaceuticals Inc. (SCLN, Financial) Friedhelm Blobel buys 10,000 shares of SCLN on 05/22/2009 at an average price of $1.71 a share.
Sciclone Pharmaceuticals Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C hepatocellular carcinoma malignant melanoma hepatitis B HIV drug-resistant tuberculosis cystic fibrosis and others. SciClone Pharmaceuticals Inc. has a market cap of $86.44 million; its shares were traded at around $1.87 with and P/S ratio of 1.6.
Recent Trades of SciClone Pharmaceuticals Inc. by CEO:
Recent Trades of SciClone Pharmaceuticals Inc. by CFO:
Sciclone Pharmaceuticals Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C hepatocellular carcinoma malignant melanoma hepatitis B HIV drug-resistant tuberculosis cystic fibrosis and others. SciClone Pharmaceuticals Inc. has a market cap of $86.44 million; its shares were traded at around $1.87 with and P/S ratio of 1.6.
Recent Trades of SciClone Pharmaceuticals Inc. by CEO:
- Buy: President & CEO Friedhelm Blobel bought 10,000 shares of SCLN stock on 05/22/2009 at the average price of $1.71; the price of the stock has increased by 9.36% since.
Recent Trades of SciClone Pharmaceuticals Inc. by CFO:
- Buy: Senior VP Finance & CFO Gary Titus bought 4,625 shares of SCLN stock on 05/22/2009 at the average price of $1.74; the price of the stock has increased by 7.47% since.
- Buy: Senior VP Finance & CFO Gary Titus bought 15,000 more shares of SCLN stock on 12/12/2008 at the average price of $1.01; the price of the stock has increased by 85.15% since.
